Chemoprevention with chlorophyllin in individuals exposed to dietary aflatoxin
Egner PA, Muñoz A, Kensler TW
Published in Mutation Research
Methodology
Review of the mechanism and clinical trial evidence for chlorophyllin as an aflatoxin chemopreventive agent
Key Findings
Chlorophyllin complexes with aflatoxin in the gut, blocking bioavailability; the clinical trial showed a 50% reduction in urinary aflatoxin-N7-guanine.
Conclusions
Chlorophyllin is a practical, low-cost intervention for populations with unavoidable dietary aflatoxin exposure.
Limitations
Narrative synthesis; relies largely on one trial and animal models; no hard clinical endpoints.
Supplements Studied
In the clinical trial, administration of CHL three times a day led to a 50% reduction in the median level of urinary excretion of aflatoxin-N(7)-guanine compared to placebo.
Study Details
Access Study
Disclosures
Funding
Public research funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.